Molecular Partners AG
SIX:MOLN

Watchlist Manager
Molecular Partners AG Logo
Molecular Partners AG
SIX:MOLN
Watchlist
Price: 4.235 CHF -2.64% Market Closed
Market Cap: 170.9m CHF
Have any thoughts about
Molecular Partners AG?
Write Note

Relative Value

The Relative Value of one MOLN stock under the Base Case scenario is 2.908 CHF. Compared to the current market price of 4.235 CHF, Molecular Partners AG is Overvalued by 31%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MOLN Relative Value
Base Case
2.908 CHF
Overvaluation 31%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
53
vs Industry
36
Median 3Y
11.1
Median 5Y
20.9
Industry
7.7
Forward
29.6
vs History
vs Industry
13
Median 3Y
-1.8
Median 5Y
-3
Industry
22.3
Forward
-2.8
vs History
vs Industry
14
Median 3Y
-2.4
Median 5Y
-3.5
Industry
21.6
vs History
vs Industry
10
Median 3Y
-2.3
Median 5Y
-3.4
Industry
24.2
vs History
52
vs Industry
57
Median 3Y
1
Median 5Y
1.4
Industry
2.5
vs History
50
vs Industry
70
Median 3Y
-0
Median 5Y
4.7
Industry
7.7
Forward
2.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.4
vs History
vs Industry
20
Median 3Y
-0.1
Median 5Y
-0.7
Industry
4.3
Forward
-0.3
vs History
vs Industry
18
Median 3Y
-0.1
Median 5Y
-0.6
Industry
4
Forward
-0.3
vs History
vs Industry
22
Median 3Y
-0.1
Median 5Y
-0.8
Industry
5.8
vs History
vs Industry
18
Median 3Y
-0.1
Median 5Y
-0.8
Industry
3.8
vs History
52
vs Industry
41
Median 3Y
-0.2
Median 5Y
6.1
Industry
4.6

Multiples Across Competitors

MOLN Competitors Multiples
Molecular Partners AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Molecular Partners AG
SIX:MOLN
170.9m CHF 16.4 -2.5 -0.2 -0.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 813 451.7 -179 721.7 -218 239.4 -215 749
US
Abbvie Inc
NYSE:ABBV
340.8B USD 6.1 67.1 16.5 25.4
US
Amgen Inc
NASDAQ:AMGN
156.4B USD 4.7 38.2 14.9 25.4
US
Gilead Sciences Inc
NASDAQ:GILD
129.7B USD 4.6 1 029.2 11.5 11.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.9B USD 10.7 -220.2 24.2 25.5
US
Epizyme Inc
F:EPE
94.1B EUR 1 863.1 -475.4 -517.7 -503.9
AU
CSL Ltd
ASX:CSL
124.1B AUD 5.3 29.9 18.6 23.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
73.8B USD 5.2 16.7 11.1 12.4
US
Seagen Inc
F:SGT
39.3B EUR 17.9 -55 -59.1 -53.4
NL
argenx SE
XBRU:ARGX
36.3B EUR 17.4 -337.7 -160.2 -104.3
P/S Multiple
Revenue Growth P/S to Growth
CH
Molecular Partners AG
SIX:MOLN
Average P/S: 3 437 763.9
16.4
42%
0.4
FR
Pharnext SCA
OTC:PNEXF
37 813 451.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
6%
1
US
Amgen Inc
NASDAQ:AMGN
4.7
3%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
4.6
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.7
9%
1.2
US
E
Epizyme Inc
F:EPE
1 863.1
N/A N/A
AU
CSL Ltd
ASX:CSL
5.3
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.2
8%
0.6
US
S
Seagen Inc
F:SGT
17.9
30%
0.6
NL
argenx SE
XBRU:ARGX
17.4
55%
0.3
P/E Multiple
Earnings Growth PEG
CH
Molecular Partners AG
SIX:MOLN
Average P/E: 236.2
Negative Multiple: -2.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -179 721.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
67.1
73%
0.9
US
Amgen Inc
NASDAQ:AMGN
38.2
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
1 029.2
22%
46.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -220.2 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -475.4 N/A N/A
AU
CSL Ltd
ASX:CSL
29.9
18%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
12%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -55 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -337.7 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
Molecular Partners AG
SIX:MOLN
Average EV/EBITDA: 16.1
Negative Multiple: -0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 239.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
9%
1.8
US
Amgen Inc
NASDAQ:AMGN
14.9
12%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
11.5
5%
2.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -517.7 N/A N/A
AU
CSL Ltd
ASX:CSL
18.6
12%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.1
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.1 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -160.2 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CH
Molecular Partners AG
SIX:MOLN
Average EV/EBIT: 20.6
Negative Multiple: -0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -215 749 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.4
25%
1
US
Amgen Inc
NASDAQ:AMGN
25.4
27%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
11.5
11%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
15%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -503.9 N/A N/A
AU
CSL Ltd
ASX:CSL
23.2
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.4
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.4 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.3 N/A N/A